We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Can Identify People with Higher Risk of Stroke

By LabMedica International staff writers
Posted on 13 Aug 2024
Print article
Image: A brain biomarker in blood samples can predict stroke (Photo courtesy of Karl Sjölin/Uppsala University)
Image: A brain biomarker in blood samples can predict stroke (Photo courtesy of Karl Sjölin/Uppsala University)

Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting approximately one-third of all individuals at some point in their lives. It is a common cause of stroke because it increases the risk of blood clots forming in the heart’s atria. Consequently, many individuals with atrial fibrillation receive anticoagulation therapy to prevent strokes. However, due to the heightened risk of serious hemorrhages from anticoagulation, only those with a moderate or high stroke risk are treated, not everyone with the condition. Therefore, accurately identifying those who would benefit from anticoagulation is crucial. While blood tests are routinely used in healthcare to assess organ function, including the heart, kidneys, and liver, no standard blood test exists to evaluate brain health in relation to cardiovascular disease. Researchers have now shown that a simple blood test reflecting brain health can determine which individuals are at increased stroke risk. This breakthrough could lead to more personalized treatment for patients with atrial fibrillation.

Researchers at Uppsala University (Uppsala, Sweden) studied the neurofilament protein, which is released from the brain under stress or low oxygen conditions, in blood samples from over 3000 individuals with atrial fibrillation. They monitored these individuals for an average of 18 months. Those with the highest levels of neurofilament in their blood were found to face the highest stroke risk. According to findings published in the journal Circulation, the risk of stroke for the quarter with the highest neurofilament levels was more than triple that of those with the lowest levels. Adding neurofilament measurements to standard cardiac blood tests from the same patients further improved stroke prediction. The next research steps will explore how various healthcare treatments affect neurofilament levels and whether this impacts the risk of stroke or death.

“We hope to be able to intervene at an earlier stage and inhibit injurious strain on the brain before it gives rise to symptoms,” said Julia Aulin, a cardiologist at Uppsala University Hospital and researcher at Uppsala University, the lead author of the study. “The findings are probably transferrable to other groups of patients with cardiovascular-related disorders, though this remains to be demonstrated. Our hope is that it will ultimately be possible to assess brain health with a simple blood test at the local health center.”

Related Links:
Uppsala University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.